In vitro cytotoxicity of 2-(2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)-N-aryl/alkyl benzamides derivatives against A549, B16-F10, DU145, HepG2 and CHO-K1 cell lines^a.

Sr. no.	Compounds	IC50 values (μM)
		A549	B16-F10	DU145	HEPG2	CHO
1	3a	29.40 ± 0.45	39.51 ± 0.13	14.83 ± 0.13	8.73 ± 0.02	NA
2	3b	19.47 ± 0.25	24.78 ± 0.70	11.56 ± 0.06	23.30 ± 0.52	NA
3	3c	15.15 ± 0.70	17.90 ± 0.17	11.49 ± 0.04	5.33 ± 0.12	NA
4	3d	21.02 ± 0.12	25.77 ± 0.13	12.84 ± 0.01	14.19 ± 0.13	NA
5	3e	11.65 ± 0.14	14.67 ± 0.05	12.05 ± 0.02	9.48 ± 0.05	69.41 ± 5.17
6	3f	16.44 ± 0.53	43.95 ± 0.26	11.06 ± 0.34	14.39 ± 0.02	NA
7	3g	30.41 ± 5.52	20.51 ± 0.91	18.65 ± 0.08	15.30 ± 0.78	NA
8	3h	34.76 ± 4.65	27.14 ± 0.68	10.44 ± 0.02	16.71 ± 1.72	94.21 ± 2.44
10	3i	19.32 ± ±0.09	32.41 ± 0.13	11.47 ± 0.19	10.09 ± 0.07	83.21 ± 1.32
11	3j	30.38 ± 1.35	34.34 ± 1.55	12.33 ± 0.17	8.74 ± 0.34	NA
12	3k	17.17 ± 0.41	29.99 ± 0.42	11.59 ± 0.06	28.68 ± 0.92	NA
13	3l	17.42 ± 0.18	28.47 ± 0.31	12.63 ± 0.08	7.77 ± 0.02	51.54 ± 2.74
14	3m	26.27 ± 1.32	41.42 ± 0.81	19.39 ± 0.14	20.18 ± 0.31	88.04 ± 3.56
15	3n	14.69 ± 0.18	14.83 ± 0.01	10.43 ± 0.13	12.30 ± 0.26	73.88 ± 2.81
16	3o	26.32 ± 1.03	16.03 ± 0.06	5.17 ± 0.07	3.02 ± 0.06	74.53 ± 9.44
17	3p	22.75 ± 0.71	31.67 ± 0.14	13.02 ± 0.03	33.88 ± 0.71	NA
18	3q	28.67 ± 1.38	36.46 ± 0.10	9.37 ± 0.03	8.51 ± 0.20	NA
19	3r	16.70 ± 0.30	33.13 ± 0.12	15.59 ± 0.07	15.95 ± 0.51	NA
19	4a	23.76 ± 0.12	22.17 ± 0.56	17.37 ± 0.32	16.04 ± 0.41	NA
20	5FU	29.64 ± 1.64	7.55 ± 0.01	16.32 ± 0.02	22.97 ± 0.27	NA
Doxorubicin		0.55 ± 0.16	0.7 ± 0.56	0.363 ± 0.01	0.72 ± 0.012	8.8.1 ± 1.04

^aA549 – Homo sapiens lung carcinoma (ATCC® CCL-185™); B16-F10 – Mus musculus mouse skin melanoma (ATCC® CRL-6475™); DU145 – Homo sapiens prostrate carcinoma (ATCC® HTB-81™); Hep G2 – Homo sapiens hepatocellular carcinoma (ATCC® HB-8065™); CHO-K1 – Cricetulus griseus chinese hamster ovary cells (ATCC® CCL-61™); 5FU, 5-flourouracil, positive control, doxorubicin as standard drug-for comparison, NA – no activity.